Vertex Pharmaceuticals VRTX
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 13, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
58 paragraphs in Risk Factors of the 10-K filed Feb 13, 2026 with nothing like them in the 10-K filed Feb 13, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
Compared with the Risk Factors in the latest 10-K of the other 59 Health care companies: a paragraph with at least half its words the same at another company is called similar, and the companies are listed under it. A paragraph most of them have is marked boilerplate. No line means no other company has one like it. This counts text; it does not say how serious a risk is.
Our success depends on our ability to develop and commercialize additional medicines.
•competition based on, among other factors, safety, efficacy, patient convenience, pricing and reimbursement.
A portion of the value attributed to our company by investors is based on the expected commercial success of JOURNAVX for acute pain and on our development programs for both acute and peripheral neuropathic pain. JOURNAVX may not gain or maintain market acceptance among physicians, patients, or payors due to various factors, including the availability of lower-cost alternatives, and sales, marketing, pricing, and/or distribution challenges associated with introducing a product into a highly competitive market. Furthermore, we may not succeed in developing JOURNAVX for additional indications or in advancing other product candidates, including NaV1.8 or NaV1.7 inhibitors, for the treatment of acute or peripheral neuropathic pain. Even if we obtain marketing approvals for these product candidates, they will face significant competition and there can be no assurance of commercial success.
The future commercial success of CASGEVY depends on physicians, patients, or payors accepting it as medically useful, cost-effective, ethical, safe, and preferred with respect to current and potential future competitive therapies, and on payors providing adequate reimbursement. In addition to risks generally associated with the commercialization of medicines, the cell collection processes, manufacturing and other procedures required to manufacture and administer CASGEVY are more complex, resource-intensive, and operationally demanding than for small molecules. For example, the cost of manufacturing CASGEVY as a percentage of revenue is significantly higher than for our CF medicines. Moreover, market acceptance continues to be dependent in part on the prevalence and severity of side effects associated with the procedure by which CASGEVY is administered, including those resulting from the myeloablative preconditioning regime. There can be no assurance that we will be able to increase or maintain our revenues from CASGEVY in future periods.
Revenues from our products depend, to a large degree, on the extent to which the products are purchased by customers, such as wholesalers, pharmacies, and hospitals, and reimbursed by third-party payors, such as government health programs, commercial insurers, and managed health care organizations. Increasingly, these third-party payors are becoming more critical in evaluating and reimbursing medicines. The containment of health care costs continues to be a priority for many governments, and drug pricing has been a focus in this effort. The U.S. federal government and state legislatures and foreign governments have shown significant and evolving interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, value-based and reference pricing, compulsory licensing, including the pursuit of so-called “march in” rights, and mandatory substitution with generic products, all of which could limit the prices of, or access to, our products. Decisions by third-party payors to not cover a product or restrict access to a product may shift over time and could reduce market acceptance of the product and limit product revenues. We must also compete to be placed on formularies of managed care providers, as exclusion of our products from a formulary would limit usage by managed care providers and patients.
In the U.S., pricing and access is primarily governed by practices of private managed care providers and institutional and governmental purchasers, federal laws and regulations related to Medicare and Medicaid, including the ACA and the IRA, and state activities, including the establishment of PDABs and price transparency rules. For example, in August 2023, the Colorado PDAB selected five drugs for an affordability review, including TRIKAFTA. Although the Colorado PDAB later found TRIKAFTA to be ineligible for an upper payment limit we cannot predict whether future reviews by the Colorado PDAB, or any other PDAB, will come to the same conclusion about TRIKAFTA or any of our other therapies, or the amount of any potential upper payment limit. Furthermore, changes to the health care system enacted as part of health care reform in the U.S., as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private payors, could result in further pricing pressures. For example, initiatives by the U.S. government to impose most-favored-nation pricing on U.S. prescription drug prices in government programs, including the recently proposed GUARD Model by the CMS. While there is significant uncertainty around the related executive orders and rulemaking, mandatory initiatives could result in reduced pricing and reimbursement for our products.
Our failure to obtain or maintain adequate prices, coverage, or reimbursement for our products would have an adverse effect on our business, revenue and results of operations, could curtail or eliminate our ability to adequately fund our research and development programs and/or could cause a decline or volatility in our stock price.
Competing products and technological advances from our competitors may negatively affect our business and market position.
Our products and product candidates face or may face competition from existing and potential competing products. See also Item 1., Business – Competition of this Annual Report on Form 10-K. Competing products may be more effective, safer, more effectively marketed, have lower prices or better coverage or reimbursement levels, eliminate or minimize the need for treatment with our products or product candidates, or have other differentiating factors that negatively affect the demand for our products or product candidates. If a competitor obtains approval and reimbursement before we do, approval and/or reimbursement of our products or product candidates could be delayed, denied, or otherwise adversely affected. We compete with an array of companies and other organizations, including those that have substantially greater resources, more mature development, manufacturing and commercial organizations, and/or other competitive advantages. Smaller companies with innovative programs or technologies are frequently acquired by and enter into collaborations with larger competitors, which may result in the acceleration or enhancement of competitive programs. We cannot predict the timing or impact of the introduction of competitive products. If a competing product is successfully developed and commercialized for a patient population we are currently treating or are seeking to treat, our revenues, business or market position could be materially adversely affected. In addition, the release of new information, including clinical data and regulatory approval timelines, by our competitors regarding competitive products or potentially competitive product candidates can affect investors’ perceptions regarding the prospects of our products and product candidates, and has caused and may in the future cause our stock price to decline or experience periods of significant volatility.
Show the other 20
The data from our product development activities may not support advancement or regulatory approval of our product candidates, or label expansions for our marketed products, or provide sufficient data to support the successful commercialization of our approved products.
Extensive testing is required for our product candidates and for new indications of our marketed products. The outcomes of such clinical and non-clinical testing are highly uncertain, may not generate sufficient safety, efficacy, or other data, and may not support regulatory approval of our product candidates. Clinical and non-clinical testing, and in particular our later-stage clinical trials, are expensive and resource intensive. The data from our preclinical studies and other research activities have in the past and may in the future fail to predict results in clinical trials. For example, despite considerable non-clinical testing, the clinical study of VX-264 in T1D did not meet its efficacy endpoint. Similarly, results from earlier-stage clinical trials may not be predictive of the results from later-stage clinical trials, or of the likelihood of approval of a product candidate for commercial sale. In addition, interim or preliminary data from a clinical trial may not be predictive of final results from the clinical trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment and treatment continues, more patient data become available, or as patients continue other treatments for their disease.
The data from our clinical programs may not support approval or successful commercialization of our product candidates, and we may be unable to recoup the significant research and development, clinical trial, acquisition-related, and other expenses incurred, which could have an adverse effect on our business, financial condition and results of operations, and/or cause our stock price to decline or experience periods of volatility.
•pause or halt our clinical trials based on their assessment of the potential or actual risks of continuing;
•require additional clinical trials, including confirmatory trials, or disagree with our clinical trial design or endpoint;
•fail to approve the facilities or processes used to manufacture a product candidate, or our dosing or delivery methods;
•grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and imposing safety monitoring requirements, or risk evaluation and mitigation strategies;
•withdraw approval of a product or indication, including when the product or indication was approved under an accelerated approval pathway and confirmatory studies were unsuccessful.
Furthermore, we periodically release new information, including clinical data, regarding our products and product candidates, which may affect investors’ perceptions regarding our products and product candidates, and cause our stock price to decline or experience periods of significant volatility. For example, our stock price decreased in August 2025 after we released Phase 2 data for VX-993 and informed investors that the FDA did not see a path toward a broad peripheral neuropathic pain label for suzetrigine at that time. The timing of the release of information by us regarding our product development programs is often beyond our control and is influenced by the timing of receipt of communications from regulators and data from our clinical trials, among other things.
If we fail to successfully conduct our clinical activities, our clinical trials or future regulatory approvals may be delayed or denied.
Conducting clinical trials is a complex, lengthy and expensive process. Our ability to complete clinical trials on our anticipated timelines depends on numerous factors, including proper and efficient protocol design, regulatory and institutional review board approval, adequate patient enrollment and retention rates, and compliance with current good clinical practices. Delays or complications in clinical trials may arise from difficulties in enrolling or retaining patients, competition from other clinical trials, the occurrence of significant and/or unexpected adverse safety events, changes in regulatory requirements, supply chain issues or disruptions at clinical trial sites. Further, we may face additional challenges identifying and enrolling sufficient patients for clinical trials for rare diseases and cell and gene therapies due to small patient populations. With respect to cell and genetic therapies there may be additional concerns regarding the safety of these more novel therapeutic approaches to the treatment of these diseases. If we or our third-party clinical trial providers, including contract research organizations (“CROs”), do not successfully conduct and manage our clinical activities or adequately comply with regulatory requirements, our clinical trials may experience delays or increased costs, and the potential regulatory approval of a product candidate or expansion of a label for a marketed product may be delayed or denied. Any delay in obtaining required regulatory approvals could adversely affect our ability to successfully commercialize a product candidate.
The extensive regulatory framework governing the health care industry could adversely affect our ability to obtain approval and market our medicines and failure to comply with these regulations could result in fines, penalties or other non-monetary remedies.
The health care industry is highly regulated and subject to complex and increasing regulations. U.S. federal and state regulators, including the FDA and comparable ex-U.S. regulators directly regulate our most critical business activities, including those related to research, development, manufacturing, and commercialization, as described in Item 1, “Business – Government Regulation.”
The process for obtaining regulatory approvals to market a product is costly and time consuming, and approvals may not be granted for future products, or additional indications of existing products, on a timely basis or at all. In addition, we cannot guarantee that we will remain compliant with applicable regulatory requirements once approval has been obtained. These requirements govern, among other things, our manufacturing practices, communications regarding our products, and reporting of safety events. Maintaining compliance with these extensive regulations is complex, expensive, and time consuming, and failure to comply may result in additional regulatory actions, including recalls, withdrawal or suspension of product approvals, civil and criminal charges, reputational harm, and fines, penalties, or other monetary or non-monetary remedies, including exclusion from receipt of payment from U.S. federal and state healthcare programs like Medicare and Medicaid. Compliance with the regulatory requirements for biologics and cell and gene therapies can be more burdensome, expensive and time-consuming than for other, better known or more extensively studied types of medicines, such as small molecules. Regulatory requirements governing cell and genetic therapy products have changed frequently and may continue to change in the future. Furthermore, risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may require different commercialization activities from those we currently utilize.
We expect that regulation of the healthcare industry will continue to evolve through political and legal action, as future proposals to reform healthcare systems are considered by U.S. and foreign governments and regulatory authorities. We cannot predict when additional changes in the healthcare industry in general, or the pharmaceutical industry in particular, will occur, or what the impact of such changes may be. For example, new proposals or requirements regarding local manufacturing of pharmaceutical products, enhanced data security and privacy measures, sustainability, importation restrictions, embargoes, or trade sanctions may negatively impact our business. In addition, our development and commercialization activities could be harmed or delayed by a shutdown of the U.S. government or events that affect the manner in which the FDA operates.
Commercialization of our products requires that we operate in compliance with applicable health care laws, including laws regulating promotional activities, prohibiting fraud and abuse and requiring reporting of government pricing information.
Our interactions with health care providers that prescribe or purchase our products are also subject to laws and regulations designed to prevent fraud and abuse in the sale and use of medicines and that place significant restrictions on the marketing practices of biopharmaceutical companies. The relationships between companies and health care providers are scrutinized and have been the target of lawsuits and investigations alleging various problematic conduct, including submission of incorrect pricing information, improper promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, and anticompetitive behavior. We are required to track and disclose financial interactions with health care providers and health care organizations, which may increase government and public scrutiny of these financial interactions. Failure to comply with these reporting requirements could result in significant civil monetary penalties. As we commercialize products for new patient populations and in new geographies, we will have more interactions with a broader set of healthcare providers and we must continue to expend significant efforts to establish, maintain and enhance systems and processes to comply with laws and regulations governing those interactions.
Government price reporting and payment regulations are also complex, requiring us to continually assess the methods by which we calculate and report pricing in accordance with these obligations. Our methodologies for calculations are inherently subject to assumptions and may be subject to review and challenge by various government agencies, which may disagree with our interpretation. If the government disagrees with our reported calculations, we may need to restate previously reported data and could be subject to additional financial and legal liability.
If we are unable to obtain, maintain and enforce our intellectual property rights, our business could be harmed. Our success depends, in significant part, on our ability to obtain, maintain, and enforce patents and intellectual property rights such as trademarks and copyrights that protect our products, product candidates, and technologies. In addition, we rely upon trade secret protection and contractual arrangements to protect certain of our proprietary information. Due to the complexity of the legal standards and factual questions relating to the patentability, validity, and enforceability of patents covering pharmaceutical and biotechnological inventions and the scope of claims made under these patents, our ability to obtain, maintain and enforce our patents is uncertain. The initial grant of patents or regulatory exclusivity in the U.S. and ex-U.S. markets depends upon decisions of the patent offices, courts, and governments in those countries. We may fail to obtain, defend or otherwise preserve patent and other intellectual property rights, including certain forms of regulatory exclusivity, and our current intellectual property rights or protections and those we obtain in the future may not be broad enough or sufficient to protect our commercial interests in all countries where we conduct business.
Difficulties in, or preclusion from, protecting our intellectual property rights in foreign jurisdictions could substantially harm our business. Third-party manufacturers may be able to sell generic versions of our products in countries that do not provide effective mechanisms for enforcement of our patents or other intellectual property rights. For example, we have experienced a violation of our intellectual property rights in Russia, where a copy product that infringes our patents has been made available. In addition, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties in certain circumstances. Compulsory licenses have been used in certain countries for market access purposes and, in some cases, as a cost-containment measure. Compulsory licenses issued for our patents may diminish or reduce revenue from those jurisdictions and negatively affect our results of operations. Third parties may also illegally distribute and sell counterfeit versions of our products. Copy or counterfeit products may not meet our rigorous manufacturing and testing standards and a patient who receives such product may be at risk for a number of dangerous health consequences. Our business and reputation could suffer harm as a result of illegally produced and distributed generic versions of our products, as well as counterfeit products sold under our brand name. The diversion of products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.
Our competitors seek to protect their products, product candidates and proprietary information through patents, trademarks, trade secrets, and copyrights. Third parties have claimed and may claim in the future that our products or other activities infringe their intellectual property rights or that our employees have misappropriated their intellectual property rights. See also Item 1., Business – Intellectual Property of this Annual Report on Form 10-K. Resolving an intellectual property infringement or other claim can be costly and time consuming and may require us to enter into license agreements, which may not be available on commercially reasonable terms. A successful claim of patent infringement or other violation or misappropriation of intellectual property rights by a third party could subject us to significant damages and/or an injunction preventing the manufacture, sale, or use of the affected product or products, and/or require us to pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.
The testing, manufacturing, marketing and use of our products and product candidates involve substantial risk of product liability claims. These claims may be made directly by consumers, patients, healthcare providers, or others. Product liability claims and lawsuits and safety alerts or product recalls, regardless of their ultimate outcome, may decrease demand for our products or any product candidate for which we obtain marketing approval, and may have a material adverse effect on our business, results of operations, reputation, and our ability to market our products. Our product liability and clinical trial insurance may not provide adequate coverage against all potential liabilities.
There continues to be a significant volume of government and regulatory investigations and litigation against companies operating in our industry, as well as robust regulatory enforcement and whistleblower claims. Investigations into aspects of our business include inquiries, subpoenas, and other types of information demands from government and regulatory authorities. We are also involved in and are subject to other various legal proceedings, including litigation, and other dispute-related proceedings. These activities require significant financial and internal resources. This includes the arbitration initiated by the third party to whom the CFF has assigned its ALYFTREK royalty rights. Please see Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for more information. The outcome of such legal proceedings, investigations or any other dispute-related proceedings are inherently uncertain and adverse developments or outcomes can result in significant expenses, monetary damages, penalties, injunctions, or other relief against us, and in the ALYFTREK arbitration, could result in higher future costs of goods if royalty fees are higher than anticipated. For a description of our litigation, investigation and other dispute-related matters, see Note P., Commitments and Contingencies — Legal Matters and Other Contingencies, included in this Annual Report on Form 10-K.
Additionally, unfavorable geopolitical events could affect our ability to interact with or conduct business with specific vendors within our global supply network or could prevent or delay the transportation of supplies or products to their planned destination. For example, we depend on China-based suppliers for portions of our supply chain. Finding alternative suppliers due to geopolitical developments or otherwise may not be feasible or could take a significant amount of time and involve significant expense due to the nature of our products and the need to obtain regulatory approvals.
In addition, we and our CMOs and corporate partners are subject to cGMP, as well as comparable regulations in other jurisdictions. Manufacturing operations are also subject to routine inspections by regulatory agencies. Even after a supplier is qualified by the regulatory authority, the supplier must continue to expend time, money and effort in the area of production and quality control to maintain full compliance with applicable regulatory requirements, including cGMP. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations. There can be no assurance that we or our CMOs and corporate partners will be able to remedy any deficiencies cited by FDA or other regulatory agencies in their inspections.
Our business depends on relationships with third parties, including activities critical to research, development, manufacturing, commercialization, and technology. For example, we rely on third parties such as CROs for the day-to-day management and oversight of our clinical trials, on CMOs for active ingredient manufacturing and finishing operations, and on logistics providers for the distribution of our products. We are expanding our relationships with CROs, CMOs, and other third parties as we enter markets in which we have no or limited experience. Failure by any of our third parties to meet their contractual, regulatory, or other obligations, any disruption in the relationship between Vertex and a third party upon whom we rely, or the failure of a third party to conduct activities in accordance with our expectations, could adversely affect the relevant research, development, manufacturing, commercial, or administrative activity and our business. The foregoing risks may be heightened as a result of the limited number or specialized nature of certain third parties, as we may not be able to replace such third party in a timely manner, on commercially reasonable terms, or at all.
The third parties upon which we rely are subject to their own operational and financial risks, as well as other difficulties, which, if realized, could negatively affect our business. If any of our third parties violate, or are alleged to have violated, any laws or regulations, including anti-corruption or anti-bribery regulations, the GDPR, or other laws and regulations, during the performance of their obligations to us, we could suffer financial and reputational harm or other negative outcomes, including possible legal consequences.
•implement and clearly communicate corporate-wide strategies and effectively prioritize resources;
•effectively leverage technology and automation where appropriate to enable efficient growth and remain competitive;
Our global operations subject us to risks that could adversely affect our business and revenue. In addition to the ex-U.S. risks we face with respect to compliance with local laws and regulatory requirements, pricing and reimbursement, intellectual property, manufacturing capabilities and supply chain, foreign exchange risks, and reliance on third parties, risks associated with operating a global biotechnology company include the potential for:
•credit risks related to our customers, which may be higher in less developed markets; and
If any of the above risks were to occur, our revenues, results of operations, financial condition or business could be materially harmed.
Similar paragraph at 1 of 59 other Health care companies: BIIB
In addition, we face certain risks as we seek to leverage artificial intelligence to optimize productivity and efficiency in various aspects of the organization. Flaws, biases, or malfunctions in these systems could lead to operational disruptions, data loss, or erroneous decision-making, impacting our operations, financial condition, and reputation. Ethical and legal challenges may arise, including biases or discrimination in generated outcomes, non-compliance with data protection regulations and laws specifically governing the use of artificial intelligence systems and tools, and lack of transparency. Furthermore, the deployment of artificial intelligence systems could expose us to increased cybersecurity threats, such as data breaches and unauthorized access. We also face competitive risks if we do not implement artificial intelligence or other machine learning technologies in a timely fashion.
Our operations may be disrupted by the occurrence of a natural disaster, catastrophic event, or by other serious accidents occurring at our facilities.
Our business development strategy, including strategic transactions and collaborations, may not be successful, and there may be delays or failures in realizing the anticipated benefits of these activities.
As part of our business strategy, we seek to enter into strategic transactions to acquire, license, or collaborate with other entities, in each case that have potential to complement and advance our ongoing research, development, manufacturing, and commercialization efforts. Over the last several years we have engaged in a number of strategic transactions and collaborations, including our acquisition of Alpine and its lead asset, povetacicept, as well as several smaller transactions and collaboration arrangements. See also Item 1., Business – Strategic Transactions of this Annual Report on Form 10-K. Our future transactions and collaborations may be similar to prior transactions, may be structured differently from prior transactions, or may involve larger transactions or later-stage assets. We face significant competition for potential strategic transactions and collaborations from a variety of other companies, some of which have significantly more financial resources and experience in business development activities. We may not complete future transactions in a timely manner, or at all, including due to the possibility that a governmental entity or regulatory body may delay or refuse to grant approval for the consummation of the transaction.
We may not realize the anticipated benefits of our completed or future strategic transactions. The product candidates or products contemplated by those transactions may be delayed or terminated at any point during research or clinical development. Even if a product is approved, we may not be able to successfully commercialize it. As a result, we may fail to generate expected revenue growth or income contribution within the anticipated timeframe or at all. We also face risks that we:
•may not effectively integrate acquired assets or businesses into our ongoing business;
•may incur additional expenses or fail to achieve anticipated cost savings related to the strategic transactions;
•may incur impairment charges related to assets acquired in any such transactions; or
In addition, future strategic transactions could result in potentially dilutive issuances of equity securities or the incurrence of debt.
Changes in foreign currency rates, interest rate risks, the value of our investment portfolio, and inflation affect our results of operations and financial condition.
Fluctuations in currency exchange rates and interest rates, changes in the value of our investment portfolio, and inflation have affected and will continue to affect our cash flows, results of operations, and financial condition. The exchange rates among our reporting currency, the U.S. dollar, and the currencies in which we do business are volatile and our efforts to mitigate against these risks may not be successful. We invest our available cash in a range of investments, including investments in cash equivalents and debt securities, and fluctuations in interest rates, among other factors, could materially negatively affect the value of this investment portfolio. In addition, systemic economic downturns, as well as inflationary pressures, such as those observed in recent periods, may adversely impact our business and financial results. See also Item 7A., Quantitative and Qualitative Disclosures About Market Risk of this Annual Report on Form 10-K.
•announcements or investor analyst commentary regarding the clinical development of our product candidates as new information, including efficacy and safety information becomes available;
•our financial guidance and/or financial results, including quarterly and annual fluctuations resulting from factors such as the timing and amount of our revenues and expenses; and
We must attract and retain highly qualified and trained scientists, as well as employees with experience in the development, manufacture, and commercialization of medicines, including biologic and cell and genetic therapies. We face intense competition for such talent from our competitors, other companies, academic institutions, and other organizations throughout our industry, especially with respect to employees with expertise in cell or genetic therapies. Our compensation program, including equity awards, may not be sufficient to retain employees, especially if our stock price declines or other employers offer more attractive opportunities. Our ability to commercialize our products and achieve our research and development objectives depends on our ability to respond effectively to these demands. If we are unable to hire and retain qualified personnel, our ability to advance our pipeline, commercialize our products, and achieve our business objectives could be materially adversely affected.
Social media is increasingly used by patients, advocacy groups, and other third parties to discuss our products and product candidates. Social media posts may include statements about efficacy or adverse events that could create reporting obligations or regulatory scrutiny. Our employees’ use of social media also presents risks, including potential noncompliance with legal or regulatory requirements, inappropriate disclosure of confidential information or personal information, and loss of intellectual property. In addition, misinformation, negative sentiment, or impersonation of our business on social media could cause reputational damage or otherwise harm our business. Failure to appropriately manage these risks could result in regulatory actions, liability, or other adverse consequences.
•our expectations or beliefs regarding any legal proceedings in which we are involved, including any litigation, arbitration or other similar proceedings involving our products, product candidates or activities;
•our ability to effectively implement artificial intelligence systems and tools;
Paragraphs in the 10-Q filed Nov 3, 2026 that were not in the one before
New in the latest 10-Q
46 paragraphs in the 10-Q filed Nov 3, 2026 with nothing like them in the 10-Q filed Aug 4, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Item 6
“CASGEVY®,” “ALYFTREK®,” and “JOURNAVX®” are registered trademarks of Vertex. “PALSONIFY®” is a registered trademark of Crinetics Pharmaceuticals, Inc., a wholly owned subsidiary of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.
Read in the 10-Q
Financial statements and notes
Payment to acquire Crinetics Pharmaceuticals, Inc., net of cash and cash equivalents (9,063.0) — acquired
Read in the 10-Q
diversity of our pipeline and support our long-term growth objectives. Crinetics’ approved medicine, PALSONIFY (paltusotine), received approval from the U.S. Food and Drug Administration in September 2025. It is a once-daily oral therapy for adults with acromegaly, a rare and debilitating condition caused by a pituitary tumor that secretes excess growth hormone. In addition to PALSONIFY, Crinetics’ most advanced pipeline candidate, atumelnant, is a once-daily oral adrenocorticotropic hormone (“ACTH”) receptor antagonist currently in Phase 3 development for congenital adrenal hyperplasia (“CAH”). Classic CAH, the most severe form of the disease, is a rare, chronic genetic condition affecting the adrenal glands that has significant unmet medical need. Atumelnant is also in Phase 2 development for people with ACTH-Dependent Cushing’s syndrome, an additional therapeutic area in which it has demonstrated potential.
Read in the 10-Q
We paid total consideration of $ 10.0 billion at the acquisition date, September 1, 2026, which included $ 9.6 billion to acquire Crinetics and $ 409.6 million to accelerate and settle unvested Crinetics equity awards. The $ 409.6 million represented post-acquisition expense, which was recorded as $ 265.5 million of “Research and development expenses” and $ 144.1 million of “Selling, general and administrative expenses.”
Read in the 10-Q
We accounted for the Crinetics Acquisition as a business combination, and allocated the purchase price to the following assets acquired and liabilities assumed:
Read in the 10-Q
Show the other 41
──────────────────────────────────────────────────────────────────────────────────────────────────── Cash consideration to acquire Crinetics’ outstanding common stock $9,055.6 Cash consideration for Crinetics’ vested and unvested equity awards 973.1 Total cash consideration paid to Crinetics 10,028.7
Read in the 10-Q
The “Inventories” acquired reflect a step-up in the fair value of acquired PALSONIFY finished goods and work-in-process inventory, which was determined using the comparative sales method. This method estimates the expected sales price of the product, reduced by all costs expected to be incurred to complete or to dispose of the inventory, as well as a profit on those costs and holding costs. The acquired inventory step-up adjustment is expensed to “Cost of sales” as the inventory is sold, and was not material to our condensed consolidated statements of income for the three and nine months ended September 30, 2026. We expect to sell the inventory over a period of approximately three
Read in the 10-Q
The “Goodwill” of $ 1.3 billion, which is not deductible for tax purposes, represents the difference between the fair value of the consideration transferred and the fair value of the assets acquired and liabilities assumed, and primarily related to establishing the deferred tax liability for the acquired intangible assets, which have no tax basis.
Read in the 10-Q
The $ 3.0 billion finite-lived asset related to the PALSONIFY marketed product that we acquired and a $ 5.1 billion in-process research and development asset related to atumelnant are recorded on our condensed consolidated balance sheet as “Other intangible assets, net.” The fair values of the intangible assets were determined using the multi-period excess earnings method to complete a discounted cash flow analysis with Level 3 fair value inputs, including significant assumptions regarding (i) the probability of technical and regulatory success related to atumelnant, (ii) estimated future cash flows from potential product sales with respect to the medicines, and (iii) earnings, which include the expected costs to continue to develop and commercialize the medicines. The PALSONIFY finite-lived asset is being amortized on a straight-lined basis through the period that we no longer have exclusive rights to market PALSONIFY, or approximately sixteen years. For the VERTEX PHARMACEUTICALS INCORPORATED
Read in the 10-Q
The “Deferred tax liability, net” of $ 1.3 billion, represents net temporary differences primarily related to intangible assets acquired and liabilities assumed, and was primarily recorded as a reduction to “Deferred tax assets” on our condensed consolidated balance sheet.
Read in the 10-Q
As of September 30, 2026, our Crinetics purchase price allocation, including for certain intangible assets acquired and tax analyses, is preliminary and will be finalized during the measurement period of up to one year from the acquisition date. Additionally, in the three and nine months ended September 30, 2026, we incurred transaction costs of $ 58.9 million directly related to the Crinetics Acquisition, which are recorded within “Selling, general and administrative expenses.” The financial results of Crinetics did not have a material effect on our revenue or net income in the three and nine months ended September 30, 2026.
Read in the 10-Q
The following table presents unaudited supplemental pro forma financial information for the three and nine months
Read in the 10-Q
ended September 30, 2026 and 2025, as if the Crinetics Acquisition had occurred on January 1, 2025:
Read in the 10-Q
The unaudited supplemental pro forma financial information was prepared using the acquisition method of accounting and is based on the historical financial information of Vertex and Crinetics. In order to reflect the occurrence of the Crinetics Acquisition on January 1, 2025, as required, the most significant adjustments reflected in the unaudited supplemental pro forma financial information are as follows:
Read in the 10-Q
• incremental amortization expense based on the fair value of the PALSONIFY intangible asset described above;
Read in the 10-Q
• incremental cost of sales related to the amortization of the step-up in the fair value of finished goods and work-in-process inventory for PALSONIFY described above;
Read in the 10-Q
• compensation expense to accelerate and settle unvested Crinetics equity awards and transaction costs directly related to the Crinetics Acquisition, reflected in the nine months ended September 30, 2025 instead of primarily in the three and nine months ended September 30, 2026;
Read in the 10-Q
• additional interest expense associated with the issuance of the 2026 Term Loan described in Note M, “Commitments and Contingencies;” and
Read in the 10-Q
• the income tax effects of the above adjustments plus Crinetics’ historical losses at applicable effective tax rates. The unaudited supplemental pro forma financial information is not necessarily indicative of what the condensed consolidated results of operations would have been had the Crinetics Acquisition been completed on January 1, 2025. In addition, the unaudited supplemental pro forma financial information is not a projection of future results of operations of the combined company, nor does it reflect the expected realization of any synergies or cost savings associated with the Crinetics Acquisition.
Read in the 10-Q
We estimate the fair value of our 2026 Term Loan, as defined in Note M, “Commitments and Contingencies,” using Level 2 inputs. The fair value of the 2026 Term Loan approximates its carrying value as of September 30, 2026, because it bears interest at a variable rate that reflects current market rates. Please refer to Note M for further details. F.Marketable Securities and Other Investments
Read in the 10-Q
As described in Note C, “Business Combination,” we acquired a total fair value of $ 461.8 million PALSONIFY inventory as part of the Crinetics Acquisition in the third quarter of 2026.
Read in the 10-Q
As described in Note C, “Business Combination,” we recorded a $ 3.0 billion finite-lived asset related to the PALSONIFY marketed product that we acquired and a $ 5.1 billion in-process research and development asset related to atumelnant as part of the purchase accounting for the Crinetics Acquisition in September 2026.
Read in the 10-Q
2026, the estimated future amortization of our finite-lived intangible assets through 2030 was as follows:
Read in the 10-Q
Stock-based compensation expense related to inventories (3.1) (4.4) (10.3) (11.2)
Read in the 10-Q
The Term Loans bear interest at a rate per annum equal to a Secured Overnight Financing Rate (“SOFR”) plus an applicable margin ranging from 0.875 % to 1.500 % for Tranche 1 and Tranche 2 Loans and from 1.000 % to 1.625 % for Tranche 3 Loans.
Read in the 10-Q
Terms Applicable to both of the 2026 Term Loan and 2026 Revolving Credit Agreement
Read in the 10-Q
In addition to the terms described above, unless specifically noted below, the 2026 Term Loan and the 2026 Revolver (the “2026 Debt Agreements”) share similar terms described below.
Read in the 10-Q
We had contract liabilities of $ 124.4 million and $ 171.8 million as of September 30, 2026 and December 31, 2025, respectively, primarily related to annual contracts with government-owned and supported customers in international markets VERTEX PHARMACEUTICALS INCORPORATED
Read in the 10-Q
• PALSONIFY (paltusotine) is a first-in-class, small molecule, once-daily oral somatostatin receptor type 2 agonist approved in the U.S. for the treatment of adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. Acromegaly is a rare and debilitating condition caused by a benign pituitary tumor that secretes excess growth hormone. There are an estimated 12,000 adults with acromegaly in the U.S. for whom PALSONIFY is an option.
Read in the 10-Q
• We recorded $10.1 million of PALSONIFY revenue in September 2026, following the closing of the Crinetics Acquisition on September 1, 2026.
Read in the 10-Q
• More than 245 million individuals have access to PALSONIFY, representing approximately 80% of U.S. covered lives.
Read in the 10-Q
• An estimated 3,200 endocrinologists treat the majority of people with acromegaly in the U.S. As of the end of the third quarter of 2026, approximately 500 of those target specialty endocrinologists are prescribing PALSONIFY.
Read in the 10-Q
• Among patients starting or switching therapy, PALSONIFY has the leading brand share at more than 40%.
Read in the 10-Q
• PALSONIFY was approved in the European Union in April 2026. We expect to begin launches in European markets in the second half of 2027. The regulatory submission for PALSONIFY in Japan was completed in April 2026, and the Ministry of Health, Labor and Welfare (the “MHLW”) has granted orphan drug designation in Japan. Pipeline
Read in the 10-Q
• We are developing atumelnant, a once-daily oral adrenocorticotropic hormone (“ACTH”) receptor antagonist, for the treatment of classic congenital adrenal hyperplasia (“CAH”), which affects approximately 17,000 people in the U.S. Classic CAH is a rare, chronic, genetic condition in which the adrenal glands are unable to make enough cortisol. Current therapies force a choice between androgen control and steroid burden, representing a significant unmet need.
Read in the 10-Q
• The Phase 3 clinical trial evaluating atumelnant in adults with CAH is a global, 32-week, randomized, double blind, placebo-controlled trial of 150 people. Enrollment and dosing are well underway, and we expect to complete enrollment in the trial in the first quarter of 2027. The FDA, the European Medicines Agency, and the MHLW in Japan have granted Orphan Drug designation to atumelnant in CAH.
Read in the 10-Q
• Atumelnant has demonstrated therapeutic potential in people with ACTH-dependent Cushing’s syndrome, another serious endocrine disease, which affects more than 10,000 people in the U.S. We have initiated a Phase 2/3 clinical trial evaluating atumelnant in people with ACTH-dependent Cushing’s syndrome. The FDA has granted Orphan Drug designation to atumelnant in ACTH-dependent Cushing’s syndrome.
Read in the 10-Q
• Given the rapid progress of VX-017, we have decided to focus on accelerating the development of VX-017, which has the potential to reach more people than zimislecel, which is designed for people with blood types A or A/B only. We expect to advance VX-017 into pivotal development in 2027. The FDA has granted Fast Track designation to VX-017.
Read in the 10-Q
Our development expenses increased by 42% and 14% in the third quarter and first nine months of 2026 as compared to the third quarter and first nine months of 2025, respectively, primarily due to $235.3 million of compensation expense associated with cash-settled unvested equity awards related to the Crinetics Acquisition, which we recorded in the third quarter of 2026, and increased outsourced services and other direct expenses. Our outsourced services and other direct expenses were lower as compared to the first nine months of 2025 due to the discontinuation of certain clinical programs during 2025.
Read in the 10-Q
• We are required to repay the $4.5 billion that we borrowed under the 2026 Term Loan as follows: $1.0 billion in August 2027, $1.0 billion in September 2028, and $2.5 billion in August 2029.
Read in the 10-Q
Market risk
In the third quarter of 2026, we entered into the 2026 Term Loan and 2026 Revolver described in Note M, “Commitments and Contingencies.” Loans under these agreements bear interest, at our option, at a base rate or a SOFR-based rate, in each case, plus an applicable margin based on our consolidated leverage ratio. We do not believe that changes in interest rates related to the 2026 Term Loan or 2026 Revolver would have a material effect on our consolidated financial statements, and we do not currently use hedge instruments to manage our exposure to these interest rate changes. As of September 30, 2026, we had $4.5 billion outstanding under the 2026 Term Loan that we borrowed on September 1, 2026 and no principal or interest outstanding under the 2026 Revolver. For amounts borrowed under the 2026 Term Loan, we estimate that a 1% unfavorable change in interest rates would result in a $45.0 million increase in our interest expense for the first year subsequent to September 1, 2026, with declining exposure thereafter.
Read in the 10-Q
Item 5
date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan. (2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.
Read in the 10-Q
On October 30, 2026, the Company appointed Jonathan Oppenheim, our Vice President, Corporate Controller, as our principal accounting officer, effective on February 15, 2027 (the “Effective Date”). On the Effective Date, Kristen Ambrose will be appointed Senior Vice President, Global Business Operations and Transformation and will cease serving as our principal accounting officer.
Read in the 10-Q
Jonathan Oppenheim, 56, has been our Vice President, Corporate Controller since August 2020. Mr. Oppenheim previously served as Controller, US Business Unit at Takeda Pharmaceutical Company, a global biopharmaceutical company, from January 2019 to August 2020. Prior to that, he served as Senior Director, Assistant Corporate Controller at Shire plc, a biotechnology company, from November 2015 to January 2019, and Director, Technical Accounting at Thermo Fisher Scientific Inc., a life sciences and clinical research company, from May 2010 to November 2015. Mr. Oppenheim received his B.S. in Accounting from the University of Massachusetts Dartmouth and is a Certified Public Accountant.
Read in the 10-Q
There are no transactions involving the Company and Mr. Oppenheim that the Company would be required to report pursuant to Item 404(a) of Regulation S-K. There is no arrangement or understanding between Mr. Oppenheim and any other person pursuant to which Mr. Oppenheim was appointed as principal accounting officer.
Read in the 10-Q
Item 6
10.2 Term Loan Agreement, dated as of July 30, 2026, by and among Vertex Pharmaceuticals Incorporated, Bank of America, N.A., and other lenders party thereto.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 3, 2026 against Item 1A of the 10-K filed Feb 13, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
This 10-Q has no Item 1A (Risk Factors) text of its own, so there is nothing to compare. Many companies leave it out when their risks have not changed.
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 13, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 13, 2025
Where each one is used
- efficacy issues: If we discover safety or efficacy issues with any of our products, commercialization efforts for the product could be negatively affected, the approved product could lose its approval, and our business could be materially harmed.
- non-clinical testing: Extensive testing is required for our product candidates and for new indications of our marketed products. The outcomes of such clinical and non-clinical testing are highly uncertain, may not generate sufficient safety, efficacy, or other data, and may not support regulatory approval of our product candidates....
- commercially reasonable: Our competitors seek to protect their products, product candidates and proprietary information through patents, trademarks, trade secrets, and copyrights. Third parties have claimed and may claim in the future that our products or other activities infringe their intellectual property rights or that our employees...
- reasonable terms: Our competitors seek to protect their products, product candidates and proprietary information through patents, trademarks, trade secrets, and copyrights. Third parties have claimed and may claim in the future that our products or other activities infringe their intellectual property rights or that our employees...
- intelligence systems: In addition, we face certain risks as we seek to leverage artificial intelligence to optimize productivity and efficiency in various aspects of the organization. Flaws, biases, or malfunctions in these systems could lead to operational disruptions, data loss, or erroneous decision-making, impacting our operations,...
- investment portfolio: Changes in foreign currency rates, interest rate risks, the value of our investment portfolio, and inflation affect our results of operations and financial condition.
- success depends: Our success depends on our ability to develop and commercialize additional medicines.
- additional medicines: Our success depends on our ability to develop and commercialize additional medicines.
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
249 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VRTX/export.csv") into a cell.